Publications by authors named "Romana Segati"
Article Synopsis
- Previous studies showed that steady-state Z-endoxifen levels (ENDOss) are linked to better cancer outcomes for women on tamoxifen.
- A study involving 203 Caucasian women evaluated the reliability of two methods for measuring CYP2D6 activity: genetic testing and a urinary dextromethorphan test.
- It was found that the urinary log(DM/DX) test was a better predictor of ENDOss than genetic testing, highlighting the importance of considering this approach in breast cancer treatment.
Objective: Although there is no standard treatment after docetaxel failure in patients with castration-resistant prostate cancer (CRPC), second-line chemotherapy is increasingly required. Its mechanism of action and toxicity profile make pemetrexed suitable for testing in this setting.
Methods And Materials: Patients with docetaxel-resistant CRPC received pemetrexed 500 mg/m(2) every 3 weeks for 6 courses.
Unlabelled: What's known on the subject? and What does the study add? Data on quality of life during docetaxel treatment in castration resistant prostate cancer was mainly provided by SWOG and TAX327 trials. In the TAX327 trial biochemical response and pain predicted survival, whereas quality of life outcomes did not. In the present study, there were no statistically significant changes in the quality of life scales during treatment except in the case of patients receiving docetaxel and estramustine, who experienced a significant decrease in pain.
View Article and Find Full Text PDFObjective: Although docetaxel (DOC) plus prednisone is currently the treatment of choice for hormone-refractory prostate cancer (HRPC), no standard therapy is available for those patients who progress during DOC treatment. The aim of this study was to evaluate whether the addition of estramustine (E) can overcome DOC resistance.
Methods: Patients who had not responded to DOC in a previous randomised phase II trial received a one-hour intravenous infusion of DOC 70 mg/m(2) on day 2 in combination with oral E 840 mg/day divided into three daily administrations on days 1-5.
Objective: To report the results of a randomized phase II trial of docetaxel with and without estramustine phosphate (EP) in patients with hormone-refractory prostate cancer (HRPC).
Patients And Methods: Patients with progressive HRPC were randomized to receive docetaxel 70 mg/m(2) on day 1 (arm A), or docetaxel 70 mg/m(2) on day 2 plus oral EP three times daily, at a total daily dose of 840 mg, on days 1-5 (arm B). The primary objective of the trial was to evaluate the activity of the treatments in terms of the response in prostate-specific antigen (PSA) level.
Prospective clinical trials of biotherapies in solid tumors: a 5-year survey.
Cancer Immunol Immunother
January 2005
Purpose: To review the content and quality of prospective clinical trials of biotherapies in solid tumors.
Methods: Data were collected from the literature between 1990 and 2002 on general study characteristics, patient and disease factors, study methodology, and factors related to completeness of reporting. Quality of phase II studies was evaluated by an ad hoc questionnaire.